The shift of leucine from blood into the intracellular microenvironment via LAT1 resulted in a decrease in pretreatment serum leucine levels in patients with LAHNSCC, contributing to either the repair of tissue protein damage by oxidative and inflammatory stress from cancer or regulation of energy homeostasis [77]. This evidence concerns the gene SLC7A5 and cancer.